Waverly Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Waverly Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$347K	Sell	2,719 -203	-7%	-$25.3K	﹤0.01%	1241
2025 Q4	$356K	Buy	+2,922	New	+$335K	﹤0.01%	1140
2023 Q3	–	Sell	-6,333	Closed	-$527K	–	415
2023 Q2	$527K	Sell	6,333 -618	-9%	-$51.7K	0.02%	240
2023 Q1	$530K	Buy	+6,951	New	+$577K	0.03%	190

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Waverly Advisors's XBI Position: Q1 2026 in Review

Waverly Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 6.9% in Q1 2026, selling an estimated $25.3K and leaving 2,719 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Waverly Advisors first reported a position in XBI in Q1 2023 and has held it in 4 quarters since. The position peaked at $530K in Q1 2023. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Waverly Advisors held 2,719 shares of State Street SPDR S&P Biotech ETF worth $347K as of Q1 2026.
Waverly Advisors sold 203 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $25.3K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Waverly Advisors's portfolio in Q1 2026, its #1241 holding.
Waverly Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 4 quarters since.
Waverly Advisors's State Street SPDR S&P Biotech ETF position peaked at $530K in Q1 2023.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.